Progetti di ricerca

Pagina 1 di 1

Understanding dyserythropoiesis to identify new therapeutic mechanisms in hereditary anemias

Data di inizio:
Data di fine:
Bando: Decreto Direttoriale n.1628 del 16-10-2020 - Bando PRIN 2020
Enti finanziatori: M.I.U.R. - MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA - UFFICIO I - Bilancio e Contabilita'. Coordinamento staff della Direzione

ARCH -AGE-RELATED CHANGES IN HEMATOPOIESIS

ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific agerelated hematological diseases (pediatric, adult, elderly), with Leggi tutto the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 4 Partner organisations (2 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.

Data di inizio:
Data di fine:
Bando: H2020- MSCA-ITN-2018
Enti finanziatori: EUROPEAN COMMISSION

Strategies to increase Hemoglobin F in beta Thalassemia: the network of molecular interactions of teh gamma globin repressors Sox6, coup TF2 and Bcl11a

Data di inizio:
Data di fine:
Bando: 2012-006 - Ricerca Scientifica in Ambito Biomedico, Ricerca Scientifica in ambito biomedico, Ricerca Scientifica in mabito biomedico, Ricerca biomedica, Ricerca scientifica in ambito biomedico
Enti finanziatori: FONDAZIONE CARIPLO

HEM_ID-HEMatopoietic cell IDentity:genetic and epigenetic regulation in normal and malignant hematopoiesis

Data di inizio:
Data di fine:
Bando: 2011-020 - FP7-PEOPLE-2011-ITN
Enti finanziatori: UNIONE EUROPEA

Genomica funzionale della transizione embrionico-adulta nell'ematopoiesi

Data di inizio:
Data di fine:
Bando: 2006-011 - PRIN 2006
a cura di Redazione Centrale, ultimo aggiornamento il 24/10/2022